Back to Newsroom

Epirus and Zalicus Announce Merger Agreement

• Merger will create a publicly traded, global biosimilar enterprise focused on improving patient access to important medicines

• Epirus closes $36 million Series B financing round

• Management to Hold Conference Call at 8:30 a.m. EDT

BOSTON, April 16, 2014 – Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, and Zalicus Inc. (NASDAQ: ZLCS) (Zalicus), announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals, Inc., and will operate under the leadership of the Epirus management team with Amit Munshi serving as the president and chief executive officer. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company’s board of directors, which will have representatives from both the existing Epirus and Zalicus boards.

Click here to read more